Tag: Daiichi Sankyo
Merck and Daiichi Sankyo collaborate on MK-6070 for global T-cell engager...
The new Agreement includes worldwide co-development and co-commercialization of DLL3 T-cell engager, excluding Japan
J&J acquisition of Ambrx bolsters cancer ADC portfolio amidst big pharma’s...
In 2022, the global ADC market for cancer treatment was valued at $7.5 billion, with Roche’s Kadcyla generating $2.2 billion, followed by Daiichi Sankyo’s Enhertu at $1.5 billion
Four pharma giants join hands to reduce environmental burden in pharma...
Astellas, Eisai, Daiichi Sankyo, and Takeda aim to ensure that society benefits from this collaboration to harmonize corporate activities with the global environment